Last CNY17.23 CNY
Change Today -0.17 / -0.98%
Volume 1.5M
600671 On Other Exchanges
Symbol
Exchange
Shanghai
As of 2:05 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

hangzhou tian-mu-shan phar-a (600671) Snapshot

Open
CNY17.40
Previous Close
CNY17.40
Day High
CNY17.40
Day Low
CNY17.09
52 Week High
10/31/14 - CNY18.15
52 Week Low
03/11/14 - CNY13.00
Market Cap
2.1B
Average Volume 10 Days
4.0M
EPS TTM
CNY0.06
Shares Outstanding
121.8M
EX-Date
08/24/08
P/E TM
271.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for HANGZHOU TIAN-MU-SHAN PHAR-A (600671)

Related News

No related news articles were found.

hangzhou tian-mu-shan phar-a (600671) Related Businessweek News

No Related Businessweek News Found

hangzhou tian-mu-shan phar-a (600671) Details

Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd manufactures and distributes pharmaceuticals, healthcare products, and medical equipment in China. The company offers its pharmaceutical products in the form of granules, eye drops, soft capsules, oral liquids, tablets, pills, capsules, and others. Its products include Pearl eyesight drops, Dendrobium soft capsules, Ho created capsules, Fule particles, Xianzhuli liquid compounds, and Lily solid gold liquids, as well as Liuweidihuang oral liquid products, such as peppermint oil, menthol, etc. The company is also involved in the biological products manufacture and distribution; food distribution; technology development; investment management; and other activities. Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd was founded in 1958 and is based in Lin'an City, China.

Founded in 1958

hangzhou tian-mu-shan phar-a (600671) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hangzhou tian-mu-shan phar-a (600671) Key Developments

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Feb 02, 2015

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Feb 02, 2015. Agenda: To consider proposal of non-public shares issuance scheme; to consider proposal of report on feasibility analysis on usage of funds raised in non-public shares issuance; and to consider the proposal of connected transactions involved in non-public shares issuance.

Hangzhou TianMuShan Plans To Raise Funds

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) plans to raise CNY 1.84 billion through private placement.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Dec 09, 2014

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Dec 09, 2014. Agenda: To consider proposal of renewing the engagement of Hua Yin Wu Zhou CAP Limited Liability Partnership (Special Ordinary Partnership) as its accounting auditor of 2014; to consider proposal of approving of Yang Zongchang Resigning from position of Officer in Charge of Financial Affairs; and to consider proposal of appointing Cheng Dengke as CFO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600671:CH CNY17.23 CNY -0.17

600671 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600671.
View Industry Companies
 

Industry Analysis

600671

Industry Average

Valuation 600671 Industry Range
Price/Earnings 100.0x
Price/Sales 10.8x
Price/Book 25.3x
Price/Cash Flow 287.0x
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANGZHOU TIAN-MU-SHAN PHAR-A, please visit www.hztmyy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.